Circulating long noncoding RNA as a potential target for prostate cancer

International Journal of Molecular Sciences

Volumn 16, Issue 6, 2015, Pages 13322-13338

  Su, Yin Jie ^a   Yu, Jin ^a   Huang, Ya Qin ^a   Yang, Jin ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Long noncoding RNA; Prostate cancer; Therapeutic target

Indexed keywords

BIOLOGICAL MARKER; BRCA2 PROTEIN; LONG UNTRANSLATED RNA; METASTASIS ASSOCIATED LUNG ADENOCARCINOMA TRANSCRIPT 1 PROTEIN; PROSTATE CANCER ASSOCIATED TRANSCRIPT 18; PROTEIN ANRIL; PROTEIN CENPF; PROTEIN CTBP1; PROTEIN MALAT1; PROTEIN PCAT 1; PROTEIN PCGEM1; PROTEIN PLNCRNA 1; PROTEIN PRNCR1; PROTEIN SCHLAP1; PROTEIN SUZ12; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER RISK; CARCINOGENESIS; DNA REPAIR; DOWN REGULATION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UPREGULATION; ANTAGONISTS AND INHIBITORS; GENE EXPRESSION REGULATION; GENETICS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; RNA, LONG NONCODING;

EID: 84931275717     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms160613322     Document Type: Review

References (70)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 2010, 127, 2893-2917.
3. Siegel, R.; Ma, J.; Zou, Z.; Jemal, A. Cancer statistics, 2014. CA Cancer J. Clin. 2014, 64, 9-29.
4. Coleman, M.P.; Quaresma, M.; Berrino, F.; Lutz, J.M.; de Angelis, R.; Capocaccia, R.; Baili, P.; Rachet, B.; Gatta, G.; Hakulinen, T. et al. Cancer survival in five continents: A worldwide population-based study (CONCORD). Lancet Oncol. 2008, 9, 730-756.
5. Gutschner, T.; Diederichs, S. The hallmarks of cancer: A long non-coding RNA point of view. RNA Biol. 2012, 9, 703-719.
6. Carter, H.B.; Pearson, J.D. PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol. Clin. N. Am. 1993, 20, 665-670.
7. Gandellini, P.; Folini, M.; Longoni, N.; Pennati, M.; Binda, M.; Colecchia, M.; Salvioni, R.; Supino, R.; Moretti, R.; Limonta, P. et al. miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res. 2009, 69, 2287-2295.
8. Tucci, P.; Agostini, M.; Grespi, F.; Markert, E.K.; Terrinoni, A.; Vousden, K.H.; Muller, P.A.; Dotsch, V.; Kehrloesser, S.; Sayan, B.S. et al. Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer. Proc. Natl. Acad. Sci. USA 2012, 109, 15312-15317.
9. Gandellini, P.; Profumo, V.; Casamichele, A.; Fenderico, N.; Borrelli, S.; Petrovich, G.; Santilli, G.; Callari, M.; Colecchia, M.; Pozzi, S. et al. miR-205 regulates basement membrane deposition in human prostate: Implications for cancer development. Cell Death Differ. 2012, 19, 1750-1760.
10. Bonci, D.; Coppola, V.; Musumeci, M.; Addario, A.; Giuffrida, R.; Memeo, L.; D’Urso, L.; Pagliuca, A.; Biffoni, M.; Labbaye, C.; et al. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14, 1271-1277.
11. Sun, T.; Wang, Q.; Balk, S.; Brown, M.; Lee, G.S.; Kantoff, P. The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res. 2009, 69, 3356-3363.
12. Park, T.Y.; Chae, J.Y.; Kim, J.W.; Oh, M.M.; Yoon, C.Y.; Moon du G. Prostate-specific antigen mass and free prostate-specific antigen mass for predicting the prostate volume of Korean men with biopsy-proven benign prostatic hyperplasia. Korean J. Urol. 2013, 54, 609-614.
13. Wang, Y.; Hu, H.L.; Liu, Z.F.; Sun, W.Z.; Chen, X.X.; Wu, C.L. Diagnosis and treatment of xanthogranulomatous prostatitis: A case report and review of the literature. Zhonghua Nan Ke Xue 2013, 19, 149-152.
14. Sanda, M.G.; Dunn, R.L.; Michalski, J.; Sandler, H.M.; Northouse, L.; Hembroff, L.; Lin, X.; Greenfield, T.K.; Litwin, M.S.; Saigal, C.S. et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N. Engl. J. Med. 2008, 358, 1250-1261.
15. Wilt, T.J.; Brawer, M.K.; Jones, K.M.; Barry, M.J.; Aronson, W.J.; Fox, S.; Gingrich, J.R.; Wei, J.T.; Gilhooly, P.; Grob, B.M. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 2012, 367, 203-213.
16. Novara, G.; Ficarra, V.; Rosen, R.C.; Artibani, W.; Costello, A.; Eastham, J.A.; Graefen, M.; Guazzoni, G.; Shariat, S.F.; Stolzenburg, J.U. et al. Systematic review and meta-analysis of perioperative outcomes and complications after robot-assisted radical prostatectomy. Eur. Urol. 2012, 62, 431-452.
17. Brawley, O.W.; Knopf, K.; Merrill, R. The epidemiology of prostate cancer part I: Descriptive epidemiology. Semin. Urol. Oncol. 1998, 16, 187-192.
18. Greene, K.L.; Meng, M.V.; Elkin, E.P.; Cooperberg, M.R.; Pasta, D.J.; Kattan, M.W.; Wallace, K.; Carroll, P.R. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: Results from cancer of the prostate strategic urological research endeavor (capsure). J. Urol. 2004, 171 6 Pt 1, 2255-2259.
19. Perkel, J.M. Visiting “noncodarnia”. BioTechniques 2013, 54, 301-304.
20. Zhang, H.; Chen, Z.; Wang, X.; Huang, Z.; He, Z.; Chen, Y. Long non-coding RNA: A new player in cancer. J. Hematol. Oncol. 2013, 6, 37.
21. Qiu, M.T.; Hu, J.W.; Yin, R.; Xu, L. Long noncoding RNA: An emerging paradigm of cancer research. Tumour Biol. 2013, 34, 613-620.
22. Yang, G.; Lu, X.; Yuan, L. LncRNA: A link between RNA and cancer. Biochim. Biophys. Acta 2014, 1839, 1097-1109.
23. Bussemakers, M.J.; van Bokhoven, A.; Verhaegh, G.W.; Smit, F.P.; Karthaus, H.F.; Schalken, J.A.; Debruyne, F.M.; Ru, N.; Isaacs, W.B. DD3: A new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999, 59, 5975-5979.
24. Tinzl, M.; Marberger, M.; Horvath, S.; Chypre, C. DD3PCA3 RNA analysis in urine—A new perspective for detecting prostate cancer. Eur. Urol. 2004, 46, 182-186; discussion 187.
25. Hessels, D.; Klein Gunnewiek, J.M.; van Oort, I.; Karthaus, H.F.; van Leenders, G.J.; van Balken, B.; Kiemeney, L.A.; Witjes, J.A.; Schalken, J.A. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44, 8-15; discussion 15-16.
26. Schalken, J.A.; Hessels, D.; Verhaegh, G. New targets for therapy in prostate cancer: Differential display code 3 (DD3PCA3), a highly prostate cancer-specific gene. Urology 2003, 62 (5 Suppl. 1), 34-43.
27. Jung, M.; Xu, C.; Spethmann, J.; Johannsen, M.; Deger, S.; Stephan, C.; Loening, S.A.; Jung, K. Re: Hessels, D.; Klein Gunnewiek, J.M.T.; van Oort, I.; Karthaus, H.F.M.; van Leenders, G.J.L.; van Balken, B.; Kiemeney, L.A.; Witjes, J.A.; Schalken, J.A. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur. Urol. 2003, 44, 8-16. Eur. Urol. 2004, 46, 271-272.
28. Ploussard, G.; Durand, X.; Xylinas, E.; Moutereau, S.; Radulescu, C.; Forgue, A.; Nicolaiew, N.; Terry, S.; Allory, Y.; Loric, S. et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur. Urol. 2011, 59, 422-429.
29. Ji, P.; Diederichs, S.; Wang, W.; Boing, S.; Metzger, R.; Schneider, P.M.; Tidow, N.; Brandt, B.; Buerger, H.; Bulk, E. et al. MALAT-1, a novel noncoding RNA, and thymosin β4 predict metastasis and survival in early-stage non-small cell lung cancer. Oncogene 2003, 22, 8031-8041.
30. Ren, S.; Wang, F.; Shen, J.; Sun, Y.; Xu, W.; Lu, J.; Wei, M.; Xu, C.; Wu, C.; Zhang, Z. et al. Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur. J. Cancer 2013, 49, 2949-2959.
31. Wang, F.; Ren, S.; Chen, R.; Lu, J.; Shi, X.; Zhu, Y.; Zhang, W.; Jing, T.; Zhang, C.; Shen, J. et al. Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. Oncotarget 2014, 5, 11091-11102.
32. Ren, S.; Liu, Y.; Xu, W.; Sun, Y.; Lu, J.; Wang, F.; Wei, M.; Shen, J.; Hou, J.; Gao, X. et al. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer. J. Urol. 2013, 190, 2278-2287.
33. Crea, F.; Watahiki, A.; Quagliata, L.; Xue, H.; Pikor, L.; Parolia, A.; Wang, Y.; Lin, D.; Lam, W.L.; Farrar, W.L. et al. Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer. Oncotarget 2014, 5, 764-774.
34. Sun, Y.; Lin, J.; Katz, A.E.; Fisher, P.B. Human prostatic carcinoma oncogene PTI-1 is expressed in human tumor cell lines and prostate carcinoma patient blood samples. Cancer Res. 1997, 57, 18-23.
35. Mehra, R.; Shi, Y.; Udager, A.M.; Prensner, J.R.; Sahu, A.; Iyer, M.K.; Siddiqui, J.; Cao, X.; Wei, J.; Jiang, H. et al. A novel RNA in situ hybridization assay for the long noncoding RNA SChLAP1 predicts poor clinical outcome after radical prostatectomy in clinically localized prostate cancer. Neoplasia 2014, 16, 1121-1127.
36. Lee, B.; Mazar, J.; Aftab, M.N.; Qi, F.; Shelley, J.; Li, J.L.; Govindarajan, S.; Valerio, F.; Rivera, I.; Thurn, T. et al. Long noncoding RNAs as putative biomarkers for prostate cancer detection. J. Mol. Diagn. 2014, 16, 615-626.
37. Tomlins, S.A.; Rhodes, D.R.; Perner, S.; Dhanasekaran, S.M.; Mehra, R.; Sun, X.W.; Varambally, S.; Cao, X.; Tchinda, J.; Kuefer, R. et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310, 644-648.
38. Schmidt, U.; Fuessel, S.; Koch, R.; Baretton, G.B.; Lohse, A.; Tomasetti, S.; Unversucht, S.; Froehner, M.; Wirth, M.P.; Meye, A. Quantitative multi-gene expression profiling of primary prostate cancer. Prostate 2006, 66, 1521-1534.
39. Petrovics, G.; Zhang, W.; Makarem, M.; Street, J.P.; Connelly, R.; Sun, L.; Sesterhenn, I.A.; Srikantan, V.; Moul, J.W.; Srivastava, S. Elevated expression of PCGEM1, a prostate-specific gene with cell growth-promoting function, is associated with high-risk prostate cancer patients. Oncogene 2004, 23, 605-611.
40. Xue, Y.; Wang, M.; Kang, M.; Wang, Q.; Wu, B.; Chu, H.; Zhong, D.; Qin, C.; Yin, C.; Zhang, Z. et al. Association between lncRNA PCGEM1 polymorphisms and prostate cancer risk. Prostate Cancer Prostatic Dis. 2013, 16, 139-144, S1.
41. Zhou, W.; Tao, Z.; Wang, Z.; Hu, W.; Shen, M.; Zhou, L.; Wen, Z.; Yu, Z.; Wu, X.; Huang, K. et al. Long noncoding RNA PCA3 gene promoter region is related to the risk of prostate cancer on Chinese males. Exp. Mol. Pathol. 2014, 97, 550-553.
42. Ren, S.; Peng, Z.; Mao, J.H.; Yu, Y.; Yin, C.; Gao, X.; Cui, Z.; Zhang, J.; Yi, K.; Xu, W. et al. RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. Cell Res. 2012, 22, 806-821.
43. Visakorpi, T.; Hyytinen, E.; Koivisto, P.; Tanner, M.; Keinanen, R.; Palmberg, C.; Palotie, A.; Tammela, T.; Isola, J.; Kallioniemi, O.P. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995, 9, 401-406.
44. Thomsen, F.B.; Brasso, K.; Christensen, I.J.; Johansson, J.E.; Angelsen, A.; Tammela, T.L.; Iversen, P.; Scandinavian Prostate Cancer Group. Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. Eur. J. Cancer 2015, 51, 1283-1292.
45. Ahmadi, H.; Daneshmand, S. Androgen deprivation therapy for prostate cancer: Long-term safety and patient outcomes. Patient Relat. Outcome Meas. 2014, 5, 63-70.
46. Molina, A.; Belldegrun, A. Novel therapeutic strategies for castration resistant prostate cancer: Inhibition of persistent androgen production and androgen receptor mediated signaling. J. Urol. 2011, 185, 787-794.
47. Takayama, K.; Kaneshiro, K.; Tsutsumi, S.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Ijichi, N.; Ouchi, Y.; Shirahige, K.; Aburatani, H. et al. Identification of novel androgen response genes in prostate cancer cells by coupling chromatin immunoprecipitation and genomic microarray analysis. Oncogene 2007, 26, 4453-4463.
48. Takayama, K.; Tsutsumi, S.; Katayama, S.; Okayama, T.; Horie-Inoue, K.; Ikeda, K.; Urano, T.; Kawazu, C.; Hasegawa, A.; Ikeo, K. et al. Integration of cap analysis of gene expression and chromatin immunoprecipitation analysis on array reveals genome-wide androgen receptor signaling in prostate cancer cells. Oncogene 2011, 30, 619-630.
49. Cui, Z.; Ren, S.; Lu, J.; Wang, F.; Xu, W.; Sun, Y.; Wei, M.; Chen, J.; Gao, X.; Xu, C. et al. The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. Urol. Oncol. 2013, 31, 1117-1123.
50. Xu, L.L.; Srikantan, V.; Sesterhenn, I.A.; Augustus, M.; Dean, R.; Moul, J.W.; Carter, K.C.; Srivastava, S. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J. Urol. 2000, 163, 972-979.
51. Takayama, K.; Horie-Inoue, K.; Katayama, S.; Suzuki, T.; Tsutsumi, S.; Ikeda, K.; Urano, T.; Fujimura, T.; Takagi, K.; Takahashi, S. et al. Androgen-responsive long noncoding RNA CTBP1-AS promotes prostate cancer. EMBO J. 2013, 32, 1665-1680.
52. Sung, Y.Y.; Cheung, E. Antisense now makes sense: Dual modulation of androgen-dependent transcription by CTBP1-AS. EMBO J. 2013, 32, 1653-1654.
53. Yang, L.; Lin, C.; Jin, C.; Yang, J.C.; Tanasa, B.; Li, W.; Merkurjev, D.; Ohgi, K.A.; Meng, D.; Zhang, J. et al. lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs. Nature 2013, 500, 598-602.
54. Srikantan, V.; Zou, Z.; Petrovics, G.; Xu, L.; Augustus, M.; Davis, L.; Livezey, J.R.; Connell, T.; Sesterhenn, I.A.; Yoshino, K. et al. PCGEM1, a prostate-specific gene, is overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 2000, 97, 12216-12221.
55. Fu, X.; Ravindranath, L.; Tran, N.; Petrovics, G.; Srivastava, S. Regulation of apoptosis by a prostate-specific and prostate cancer-associated noncoding gene, PCGEM1. DNA Cell Biol. 2006, 25, 135-141.
56. Chung, S.; Nakagawa, H.; Uemura, M.; Piao, L.; Ashikawa, K.; Hosono, N.; Takata, R.; Akamatsu, S.; Kawaguchi, T.; Morizono, T. et al. Association of a novel long non-coding RNA in 8q24 with prostate cancer susceptibility. Cancer Sci. 2011, 102, 245-252.
57. Prensner, J.R.; Sahu, A.; Iyer, M.K.; Malik, R.; Chandler, B.; Asangani, I.A.; Poliakov, A.; Vergara, I.A.; Alshalalfa, M.; Jenkins, R.B. et al. The lncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer. Oncotarget 2014, 5, 1434-1438.
58. Wang, L.; Han, S.; Jin, G.; Zhou, X.; Li, M.; Ying, X.; Wang, L.; Wu, H.; Zhu, Q. Linc00963: A novel, long non-coding RNA involved in the transition of prostate cancer from androgen-dependence to androgen-independence. Int. J. Oncol. 2014, 44, 2041-2049.
59. Prensner, J.R.; Iyer, M.K.; Balbin, O.A.; Dhanasekaran, S.M.; Cao, Q.; Brenner, J.C.; Laxman, B.; Asangani, I.A.; Grasso, C.S.; Kominsky, H.D. et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat. Biotechnol. 2011, 29, 742-749.
60. Tripathi, V.; Ellis, J.D.; Shen, Z.; Song, D.Y.; Pan, Q.; Watt, A.T.; Freier, S.M.; Bennett, C.F.; Sharma, A.; Bubulya, P.A. et al. The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol. Cell 2010, 39, 925-938.
61. Hutchinson, J.N.; Ensminger, A.W.; Clemson, C.M.; Lynch, C.R.; Lawrence, J.B.; Chess, A. A screen for nuclear transcripts identifies two linked noncoding RNAs associated with SC35 splicing domains. BMC Genomics 2007, 8, 39.
62. Prensner, J.R.; Iyer, M.K.; Sahu, A.; Asangani, I.A.; Cao, Q.; Patel, L.; Vergara, I.A.; Davicioni, E.; Erho, N.; Ghadessi, M. et al. The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex. Nat. Genet. 2013, 45, 1392-1398.
63. Yap, K.L.; Li, S.; Munoz-Cabello, A.M.; Raguz, S.; Zeng, L.; Mujtaba, S.; Gil, J.; Walsh, M.J.; Zhou, M.M. Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol. Cell 2010, 38, 662-674.
64. Kotake, Y.; Nakagawa, T.; Kitagawa, K.; Suzuki, S.; Liu, N.; Kitagawa, M.; Xiong, Y. Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15INK4B tumor suppressor gene. Oncogene 2011, 30, 1956-1962.
65. Lustig-Yariv, O.; Schulze, E.; Komitowski, D.; Erdmann, V.; Schneider, T.; de Groot, N.; Hochberg, A. The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene? Oncogene 1997, 15, 169-177.
66. Ariel, I.; Sughayer, M.; Fellig, Y.; Pizov, G.; Ayesh, S.; Podeh, D.; Libdeh, B.A.; Levy, C.; Birman, T.; Tykocinski, M.L. et al. The imprinted H19 gene is a marker of early recurrence in human bladder carcinoma. Mol. Pathol. 2000, 53, 320-323.
67. Zhu, M.; Chen, Q.; Liu, X.; Sun, Q.; Zhao, X.; Deng, R.; Wang, Y.; Huang, J.; Xu, M.; Yan, J. et al. lncRNA H19/miR-675 axis represses prostate cancer metastasis by targeting TGFBI. FEBS J. 2014, 281, 3766-3775.
68. Pickard, M.R.; Mourtada-Maarabouni, M.; Williams, G.T. Long non-coding RNA GAS5 regulates apoptosis in prostate cancer cell lines. Biochim. Biophys. Acta 2013, 1832, 1613-1623.
69. Prensner, J.R.; Chen, W.; Iyer, M.K.; Cao, Q.; Ma, T.; Han, S.; Sahu, A.; Malik, R.; Wilder-Romans, K.; Navone, N. et al. PCAT-1, a long noncoding RNA, regulates BRCA2 and controls homologous recombination in cancer. Cancer Res. 2014, 74, 1651-1660.
70. Hung, C.L.; Wang, L.Y.; Yu, Y.L.; Chen, H.W.; Srivastava, S.; Petrovics, G.; Kung, H.J. A long noncoding RNA connects c-Myc to tumor metabolism. Proc. Natl. Acad. Sci. USA 2014, 111, 18697-18702.